研究業績
英文論文 2024年度
- Ouchi K，Takahashi S，Sasaki K，Yoshida Y，Taniguchi S，Kasahara Y，Komine K，Imai H，Saijo K，Shirota H，Takahashi M，Ishioka C. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial. Int J Colorectal Dis 39. 89. Jun 11 (2024)
- Yoshida Y，Takahashi M，Komine K，Taniguchi S，Yamada H，Sasaki K，Umegaki S，Kawamura Y，Kasahara Y，Ouchi K，Imai H，Saijo K，Shirota H，Takenaga N，Ishioka C. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors. Intern Med Jun 13 (2024)
- Ikari T，Hiratsuka Y，Oishi T，Miyashita M，Morita T，Mack J W，Okada Y，Chiba N，Ishioka C，Inoue A. Preferred and Actual Places of Death Among Patients with Advanced Cancer: A Single-centre Cohort Study in Japan. Indian J Palliat Care 30. 268-274. Jul-Sep (2024)
- Tanita K，Koseki Y，Kumar S，Taemaitree F，Mizutani A，Nakatsuji H，Suzuki R，Dao A T N，Fujishima F，Tada H，Ishida T，Saijo K，Ishioka C，Kasai H. Carrier-free nano-prodrugs for minimally invasive cancer therapy. Nanoscale 16. 15256-15264. Aug 15 (2024)
- Yoshida Y，Takahashi M，Taniguchi S，Numakura R，Komine K，Ishioka C. Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAF(V600E) colorectal cancer. Cancer Sci Aug 22 (2024)
- Takahashi S，Sato N，Kaneko K，Masuda N，Kawai M，Hirakawa H，Nomizu T，Iwata H，Ueda A，Ishikawa T，Bando H，Inoue Y，Ueno T，Ohno S，Kubo M，Yamauchi H，Okamoto M，Tokunaga E，Kamigaki S，Aogi K，Komatsu H，Kitada M，Uemoto Y，Toyama T，Yamamoto Y，Yamashita T，Yanagawa T，Yamashita H，Matsumoto Y，Toi M，Miyashita M，Ishida T，Fujishima F，Sato S，Yamaguchi T，Takahashi F，Ishioka C. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts. Transl Oncol 48. 102060. Oct (2024)
- Kasahara Y，Saijo K，Ueta R，Numakura R，Sasaki K，Yoshida Y，Taniguchi S，Ouchi K，Komine K，Imai H，Shirota H，Takahashi M，Ishioka C. Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab. Sci Rep 14. 28255. Nov 16 (2024)
- Iwasaki T，Shirota H，Sasaki K，Ouchi K，Nakayama Y，Oshikiri H，Otsuki A，Suzuki T，Yamamoto M，Ishioka C. Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study. Cancer Sci 115. 4034-4044. Dec (2024)
- Sho Umegaki， Masanobu Takahash，Junko Hasegawa-Minato， Maako Kawamura ，Sakura Taniguchi ，Keigo Komine，Hideki Tokunaga，Kota Ouchi， Hiroo Imai， Ken Saijo，Hidekazu Shirota，Fumiyoshi Fujishima， Muneaki Shimada，Yoko Aoki，Chikashi Ishioka. Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer. International Cancer Conference Journal https://doi.org/10.1007/s13691-025-00753-2. (2025)